What question did this study set out to answer?

Determine whether treating underlying small-cell lung carcinoma leads to neurological improvement in patients with Lambert-Eaton myasthenic syndrome.

October 1, 1990Neurology

Response of the Lambert‐Eaton myasthenic syndrome to treatment of associated small‐cell lung carcinoma

View Full Paper

Ask AI

Bookmark

Authors

CCColin ChalkMcGill University NMN.M.F. MurrayBrown University JNJohn Newsom–DavisUniversity of Oxford

Discussion

Member takes

Implication

Cohort study demonstrates neurological recovery following tumor therapy in small-cell lung carcinoma-associated Lambert-Eaton syndrome, indicating the value of aggressive combined treatment.

Key Points

Determine whether treating underlying small-cell lung carcinoma leads to neurological improvement in patients with Lambert-Eaton myasthenic syndrome.
Evaluated outcomes in 16 patients with histologically verified small-cell carcinoma and associated Lambert-Eaton myasthenic syndrome.
Administered tumor-specific therapy (chemotherapy, radiation therapy, or resection) to 13 patients, with most also receiving pharmacologic and immunologic treatments for myasthenia.
Monitored disease severity via electromyographic measurement of compound muscle action potential amplitude in the abductor digiti minimi muscle.
Among 11 patients surviving more than 2 months after tumor therapy, 7 achieved substantial neurologic improvement (including 1 complete remission at 7 years) and 3 experienced transient improvement.
Compound muscle action potential amplitude increased significantly from baseline to final follow-up (p < 0.01; n = 11).
A pretreatment compound muscle action potential amplitude greater than 3.0 mV served as a favorable prognostic indicator for recovery.

Cite This Study

Chalk et al. (1990) studied this question.

synapsesocial.com/papers/6aaf24d6a5af4fa898d05bc7 https://doi.org/10.1212/wnl.40.10.1552

View Full Paper

Ask AI

Bookmark

Implication

Cohort study demonstrates neurological recovery following tumor therapy in small-cell lung carcinoma-associated Lambert-Eaton syndrome, indicating the value of aggressive combined treatment.

Response of the Lambert‐Eaton myasthenic syndrome to treatment of associated small‐cell lung carcinoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Response of the Lambert‐Eaton myasthenic syndrome to treatment of associated small‐cell lung carcinoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider